NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) approved…Original Article
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX (tecovirimat)
